Chemically Induced Experimental Models of Absence Epilepsy

Chemical-Induced Seizures: Mechanisms, Consequences and Treatment

Volumn , Issue , 2011, Pages 67-79

  Aker, Rezzan Gülhan ^a   Onat, Filiz Yilmaz ^a   Kinay, Demet ^b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Bakirkoy Research Hospital for Psychiatric and Neurological Diseases   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882843720     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805274511101010067     Document Type: Chapter

References (61)

1. Berg AT, Berkovic SF, Brodie MJ et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-85
2. Snead OC, 3rd. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37: 146-57
3. Panayiotopoulos CP, Obeid T, Waheed G. Differentiation of typical absence seizures in epileptic syndromes. A video EEG study of 224 seizures in 20 patients. Brain 1989;112 ( Pt 4): 1039-56.
4. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol 2003; 20: 426-41
5. Nolan M, Bergazar M, Chu B, Cortez MA, Snead OC, 3rd. Clinical and neurophysiologic spectrum associated with atypical absence seizures in children with intractable epilepsy. J Child Neurol 2005; 20: 404-10
6. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001; 3: 379-403.
7. Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol Sci 2003; 24: 542-9
8. Goren MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev 2007; 13: 224-39
9. Raspall-Chaure M, Neville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol 2008; 7: 57-69
10. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362: 790-9
11. Snead OC, 3rd, Depaulis A, Vergnes M, Marescaux C. Absence epilepsy: advances in experimental animal models. Adv Neurol 1999; 79: 253-78
12. Nehlig A, Vergnes M, Boyet S, Marescaux C. Metabolic activity is increased in discrete brain regions before the occurrence of spike-and-wave discharges in weanling rats with genetic absence epilepsy. Brain Res Dev Brain Res 1998; 108: 69-75
13. Nehlig A, Vergnes M, Boyet S, Marescaux C. Local cerebral glucose utilization in adult and immature GAERS. Epilepsy Res 1998; 32: 206-12
14. Velazquez JL, Huo JZ, Dominguez LG, Leshchenko Y, Snead OC, 3rd. Typical versus atypical absence seizures: network mechanisms of the spread of paroxysms. Epilepsia 2007; 48: 1585-93
15. Cortez MA, McKerlie C, Snead OC, 3rd. A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. Neurology 2001; 56: 341-9
16. Marescaux C, Vergnes M, Depaulis A. Genetic absence epilepsy in rats from Strasbourg--a review. J Neural Transm Suppl 1992; 35: 37-69
17. Meeren H, van Luijtelaar G, Lopes da Silva F, Coenen A. Evolving concepts on the pathophysiology of absence seizures: the cortical focus theory. Arch Neurol 2005; 62: 371-6
18. Meeren HK, Pijn JP, Van Luijtelaar EL, Coenen AM, Lopes da Silva FH. Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J Neurosci 2002; 22: 1480-95
19. Polack PO, Guillemain I, Hu E, Deransart C, Depaulis A, Charpier S. Deep layer somatosensory cortical neurons initiate spike-and-wave discharges in a genetic model of absence seizures. J Neurosci 2007; 27: 6590-9
20. Budde T, Pape HC, Kumar SS, Huguenard JR. Thalamic, thalamocortical, and corticocortical models of epilepsy with an emphasis on absence seizures. In: Pitkanen A, Moshe S, Schwartzkroin P, Eds. Models of Seizures and Epilepsy. Academic Press 2006; pp. 73-88.
21. Fisher RS. Animal models of the epilepsies. Brain Res Brain Res Rev. 1989;14: 245-78.
22. Engel J. Experimental animal models of epilepsy: classification and relevance to human epileptic phenomena. Epilepsy Res Suppl 1992; 8: 9-20
23. Sarkisian MR. Overview of the Current Animal Models for Human Seizure and Epileptic Disorders. Epilepsy Behav 2001; 2: 201-16
24. Pitkanen A, Moshe, S., Schwartkroin, P., Eds. Models of Seizures and Epilepsy. Academic Press; 2006.
25. Marcus EM. Experimental Models of Petit Mal Epilepsy. In: Purpura DP, Penry, J.K., Tower, D., Woodbury, D.M., Walter, R., Eds. Experimetal Models of Epilepsy-A Manual for the Laboratory Worker. New York: Raven Press 1972; pp. 113-46.
26. Velisek L. Models of Chemically-Induced Acute Seizures. In: Pitkanen A, Moshe, S., Schwartkroin, P., editor. Models of Seizures and Epilepsy. Academic Press 2006; pp. 127-52.
27. Zhang X, Le Gal La Salle G, Ridoux V, Yu PH, Ju G. Fos oncoprotein expression in the rat forebrain following muscimolinduced absence seizures. Neurosci Lett 1996; 210: 169-72
28. Snead OC, 3rd, Bearden LJ. The epileptogenic spectrum of opiate agonists. Neuropharmacology 1982; 21: 1137-44
29. Kato K, Urino T, Hori T et al. Experimental petit mal-like seizure induced by microinjection of kainic acid into the unilateral mediodorsal nucleus of the thalamus. Neurol Med Chir (Tokyo) 2008 ; 48: 285-90.
30. Macdonald RL, Barker JL. Specific antagonism of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: a common mode of convulsant action. Neurology 1978; 28: 325-30
31. Avoli M. Feline generalized penicillin epilepsy. Ital J Neurol Sci 1995; 16: 79-82
32. Prince DA, Farrell, D. Centrencephalic spikewave discharges following parenteral penicillin injection in the cat. Neurology 1969; 19: 309-10
33. Kostopoulos GK. Spike-and-wave discharges of absence seizures as a transformation of sleep spindles: the continuing development of a hypothesis. Clin Neurophysiol 2000; 111( Suppl 2): S27-38.
34. Olsen RW. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol Cell Biochem 1981; 39: 261-79
35. White HS, Johnson M, Wolf HH, Kupferberg HJ. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci 1995; 16: 73-7
36. Wong CG, Gibson KM, Snead OC, 3rd. From the street to the brain: neurobiology of the recreational drug gammahydroxybutyric acid. Trends Pharmacol Sci 2004; 25: 29-34
37. Bernasconi R, Mathivet P, Bischoff S, Marescaux C. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 1999; 20: 135-41.
38. Bessman SP, Fishbein WN. Gamma-Hydroxybutyrate, a Normal Brain Metabolite. Nature 1963; 200: 1207-8
39. Nelson T, Kaufman E, Kline J, Sokoloff L. The extraneural distribution of gamma-hydroxybutyrate. J Neurochem. 1981; 37: 1345-8
40. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-61
41. Benavides J, Rumigny JF, Bourguignon JJ et al. High affinity binding sites for gamma-hydroxybutyric acid in rat brain. Life Sci 1982; 30: 953-61
42. Erhardt S, Andersson B, Nissbrandt H, Engberg G. Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by gamma-hydroxybutyric acid (GHBA) are specifically induced by activation of GABA(B) receptors. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 611-9
43. Gervasi N, Monnier Z, Vincent P et al. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003; 23(36): 11469-78.
44. Lingenhoehl K, Brom R, Heid J et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 1999; 38: 1667-73
45. Wu Y, Ali S, Ahmadian G et al. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004; 47: 1146-56
46. Castelli MP, Mocci I, Pistis M et al. Stereoselectivity of NCS-382 binding to gamma-hydroxybutyrate receptor in the rat brain. Eur J Pharmacol 2002; 446: 1-5
47. Bearden LJ, Snead OC, Healey CT, Pegram GV. Antagonism of gamma-hydroxybutyric acid-induced frequency shifts in the cortical EEG of rats by dipropylacetate. Electroencephalogr Clin Neurophysiol 1980; 49: 181-3
48. Depaulis A, Bourguignon JJ, Marescaux C et al. Effects of gamma-hydroxybutyrate and gamma-butyrolactone derivates on spontaneous generalized non-convulsive seizures in the rat. Neuropharmacology 1988; 27: 683-9
49. Crunelli V, Leresche N. Action of gamma-hydroxybutyrate on neuronal excitability and underlying membrane conductances In: Tunnicliff G, Cash CD, Eds. Gamma-hydroxybutyrate: Molecular, functional and clinical aspects. New York: Taylor and Francis 2002; pp. 75-110.
50. Carcak N, Aker RG, Ozdemir O, Demiralp T, Onat FY. The relationship between age-related development of spike-andwave discharges and the resistance to amygdaloid kindling in rats with genetic absence epilepsy. Neurobiol Dis 2008; 32: 355-63
51. Ryu MJ, Kim D, Kang UB et al. Proteomic analysis of gamma-butyrolactone-treated mouse thalamus reveals dysregulated proteins upon absence seizure. J Neurochem 2007; 102: 646-56
52. Hu RQ, Cortez MA, Man HY, Wang YT, Snead OC, 3rd. Alteration of GLUR2 expression in the rat brain following absence seizures induced by gamma-hydroxybutyric acid. Epilepsy Res 2001; 44: 41-51
53. Fariello RG, Golden GT. The THIP-induced model of bilateral synchronous spike and wave in rodents. Neuropharmacology 1987; 26: 161-5
54. Vergnes M, Marescaux C, Micheletti G, Rumbach L, Warter JM. Blockade of "antiabsence" activity of sodium valproate by THIP in rats with petit mal-like seizures. Comparison with ethosuximide. J Neural Transm 1985; 63: 133-41
55. Lundbeck. Discontinuation of development program for gaboxadol in insomnia. 2007 [03-03-2010.]; Available from: http://www.lundbeck.com/investor/Presentations/Financial_presentations/Files/Teleconference_pres/Teleconference_gaboxadol.pdf.
56. Smith KA, Bierkamper GG. Paradoxical role of GABA in a chronic model of petit mal (absence)-like epilepsy in the rat. Eur J Pharmacol 1990; 176: 45-55
57. Persad V, Cortez MA, Snead OC, 3rd. A chronic model of atypical absence seizures: studies of developmental and gender sensitivity. Epilepsy Res 2002; 48: 111-9
58. Huo JZ, Cortez MA, Snead OC, 3rd. GABA receptor proteins within lipid rafts in the AY-9944 model of atypical absence seizures. Epilepsia 2009; 50: 776-88
59. Serbanescu I, Cortez MA, McKerlie C, Snead OC, 3rd. Refractory atypical absence seizures in rat: a two hit model. Epilepsy Res 2004; 62: 53-63
60. Chevassus-au-Louis N, Baraban SC, Gaiarsa JL, Ben-Ari Y. Cortical malformations and epilepsy: new insights from animal models. Epilepsia 1999; 40: 811-21
61. Baulac M, Pitkänen A. Research Priorities in Epilepsy for the Next Decade-A Representative View of the European Scientific Community. Epilepsia 2008.